FDA Approves First Brain-Crossing Therapy for Hunter Syndrome, Offering New Hope for Children

March 26, 2026

The U.S. Food and Drug Administration (FDA) has ushered in a new era of treatment for one of the most challenging rare genetic disorders. On March 24, 2026, the agency granted accelerated approval to AVLAYAH™ (tividenofusp alfa-eknm), the first enzyme replacement therapy (ERT) designed to cross the blood-brain barrier for children with Hunter syndrome (mucopolysaccharidosis type II, or MPS II).

This landmark decision provides the first new treatment option in nearly two decades for a progressive condition that affects the brain, heart, and lungs. By utilizing an innovative “molecular ferry” system, AVLAYAH aims to treat the devastating neurological decline that current therapies cannot reach.

Understanding the “Brain Barrier” Challenge

Hunter syndrome is an X-linked lysosomal storage disorder that primarily affects males, occurring in approximately 1 in 100,000 to 1 in 150,000 live births. It is caused by a deficiency of the enzyme iduronate-2-sulfatase (IDS). Without this enzyme, long-chain sugar molecules called glycosaminoglycans (GAGs) build up in cells throughout the body, leading to organ damage, skeletal deformities, and—in its most severe form—progressive cognitive impairment.

Since 2005, the standard of care has been idursulfase, an ERT that improves physical endurance and respiratory function. However, idursulfase molecules are too large to pass through the blood-brain barrier, a protective semi-permeable membrane that shields the brain from toxins but also blocks most medicines. As a result, while a child’s body might improve on standard ERT, their brain continues to suffer from the toxic buildup of sugars.

AVLAYAH changes this dynamic through Denali Therapeutics’ proprietary Transport Vehicle (TV) platform. This technology fuses the IDS enzyme to an engineered molecule that “tricks” the brain’s natural transport system. By targeting transferrin receptors—essentially the brain’s gateway for iron—the therapy is ferried directly into the central nervous system.

Key Clinical Findings: A 91% Reduction in Brain Toxins

The FDA’s accelerated approval was based on data from a Phase 1/2 clinical trial involving 44 patients. The primary metric for success was the reduction of heparan sulfate (HS)—a specific sugar molecule—in the cerebrospinal fluid (CSF).

The trial results were significant:

• Biomarker Reduction: Patients saw a 91% reduction in CSF heparan sulfate levels from baseline by week 24.

• Normalization: By the 24-week mark, 93% of treated patients achieved HS levels within the range seen in healthy individuals without Hunter syndrome.

• Clinical Stabilization: Data published in the New England Journal of Medicine (January 1, 2026) indicated that repeated dosing led to stabilization or improvement in adaptive behavior, cognition, and hearing, alongside a normalization of liver volume.

“AVLAYAH represents the first real shot at modifying the brain-based aspects of Hunter syndrome,” said Dr. Sarah L. Johnston, a pediatric metabolic-disease specialist not involved in the trials. “For decades, families had to choose between treating the body and accepting the inexorable decline in the brain. This approval means we now have a biologic that can, at least theoretically, address both.”

Public Health Implications and Early Intervention

With fewer than 1,500 diagnosed cases worldwide, Hunter syndrome is often missed in its early stages. Diagnosis usually occurs between ages 2 and 4, once symptoms like developmental regression, coarse facial features, and joint stiffness become apparent.

Experts emphasize that the approval of a brain-targeted therapy increases the urgency for early detection. “The sooner we can start AVLAYAH before significant brain injury occurs, the greater the chance of preserving skills and quality of life,” noted Dr. Michael Chen, a pediatric neurologist specializing in lysosomal disorders. “This reinforces the need for expanded newborn screening and genetic testing in boys with developmental delay.”

Navigating Risks and Limitations

While the approval is a victory for the rare disease community, it comes with caveats. The most common side effects reported were infusion-related reactions, such as rashes or fever. These are typical for intravenous biologics and are generally managed with pre-medications like antihistamines.

Furthermore, because this was an accelerated approval, it is contingent upon the results of the ongoing Phase 2/3 COMPASS trial. This global study is comparing AVLAYAH head-to-head with the older idursulfase to confirm long-term clinical benefits. If the confirmatory data fails to prove a meaningful improvement in cognitive or daily functioning, the FDA reserves the right to withdraw the drug from the market.

“We’ve seen promising biomarker data that did not fully translate to quality-of-life improvements in other neurodegenerative conditions,” cautioned Dr. Evelyn Ross, a bioethicist and pediatric-neurology researcher. “Families deserve transparent, ongoing updates as the COMPASS trial unfolds.”

The Road Ahead for Families

For families, the practical reality of AVLAYAH involves weekly intravenous infusions. While Denali has not yet disclosed the final price, therapies for ultra-rare diseases frequently cost several hundred thousand dollars per year, raising concerns about insurance coverage and global access.

Despite these hurdles, the medical community views this as a watershed moment. By successfully “breaking the barrier” of the brain, AVLAYAH may provide a blueprint for treating other lysosomal storage disorders and neurodegenerative diseases.

For now, clinicians suggest that parents of children with neurologic forms of MPS II discuss the following with their care teams:

1. Early Initiation: Evaluating if the child is a candidate for AVLAYAH before significant brain injury occurs.

2. Integrated Care: Continuing supportive therapies—such as physical therapy and hearing aids—alongside the new infusion.

3. Monitoring: Closely tracking cognitive and adaptive milestones to gauge the therapy’s impact on the child’s specific progression.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

Reference Section

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-denalis-genetic-disorder-therapy-2026-03-25/